INTRODUCTION {#S1}
============

Antibody-mediated inflammatory responses are critical in immunity against infectious organisms. These responses can promote pathogen clearance but can also exacerbate symptoms during infections ([@R11]). Antibody-mediated inflammation is triggered when pathogens or infected cells are bound by immunoglobulin G (IgG) antibodies, forming immune complexes that signal through Fc gamma receptors (FcγRs) on effector cells. The outcome of effector cell responses depends on the balance of activating to inhibitory (A/I) FcγR signaling that arises from interactions with Fc domains within immune complexes. Activating FcγRs contain immunoreceptor tyrosine-based activation motifs (ITAMs), while the inhibitory FcγR balances this activity through immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling. One factor that modulates the ratio of A/I FcγR signaling is the glycosylation state of the IgG Fc domains within immune complexes. For example, sialylation of the Fc promotes anti-inflammatory effector responses, whereas absence of core fucosylation, afucosylation, of the Fc is pro-in-flammatory due to increasing affinity of the Fc for the activating FcγRIIIa, found on natural killer (NK) cells, as well as on subsets of macrophages and monocytes ([@R3]; [@R11]; [@R42]). The second major determinant of A/I FcγR signaling by immune complexes is the distribution of IgG subclasses within the complex, with IgG1 being the dominant subclass promoting pro-inflammatory responses and IgG2 signaling through the inhibitory FcγR ([@R41]).

Dengue virus infections are unusual in that non-neutralizing anti-dengue virus IgGs can play a central role in triggering progression to the severe forms of disease through antibody-dependent enhancement (ADE) mechanisms ([@R2]; [@R13]; [@R15]; [@R23]; [@R24]; [@R30]; [@R34]; [@R48]; [@R59]). ADE can occur in the presence of reactive, non-neutralizing IgGs, as are found in secondary heterologous dengue infections or in primary infections in infants of dengue-immune mothers due to acquisition of anti-dengue virus IgGs during gestation ([@R24]; [@R31]; [@R50]). These antibodies are thought to promote disease by forming immune complexes with the virus that modulate infection in FcγR-bearing cells, primarily monocytes and macrophages, leading to higher viral titers and altered cytokine production during infection ([@R5]; [@R18]; [@R32]; [@R54]). Still, the vast majority of dengue infections that occur in the presence of non-neutralizing IgGs are asymptomatic, and specific features of antibodies that enhance one's basal susceptibility for dengue disease are unknown. Importantly, mortality rates in severe dengue can exceed 20% when patients are not hospitalized, but can be reduced to \<1% with in-patient care ([@R2]; [@R22]). Therefore, the identification of serologic markers for increased baseline susceptibility to dengue disease could dramatically reduce mortality associated with these viruses by enabling early hospitalization of those at highest risk for disease progression.

Because maternal IgGs are transferred to the fetus during gestation, we hypothesized that the repertoire of maternal anti-dengue virus IgG Fc domains might impact basal susceptibility of infants to disease during dengue virus infections. To address this, we performed a global analysis of maternal anti-dengue IgG Fc domain features from a prospective cohort of mothers and infants in a dengue-endemic region of the Philippines in order to define characteristics that predicted progression to significant infant dengue disease. We found that maternal anti-dengue IgGs enriched for afucosylated Fc glycoforms predicted clinically significant disease in their infants during primary dengue infections. Because afucosylation enhances affinity of the Fc for FcγRIIIa, this suggested a role for this receptor in the pathogenesis of dengue disease. We therefore performed studies to dissect the mechanism by which FcγRIIIa and afucosylated IgGs impact dengue virus infections. Our findings identify a pathway by which dengue replication can be enhanced through a FcγRIIIa signaling mechanism requiring the calcineurin signaling network. These studies identify a mechanistic basis for differential susceptibility to dengue disease based on the presence of afucosylated anti-dengue IgGs and suggest novel strategies for the treatment of dengue virus infections.

RESULTS {#S2}
=======

Maternal Anti-Dengue Fucosylation Predicts Susceptibility to Clinically Significant Disease during Infant Dengue Infections {#S3}
---------------------------------------------------------------------------------------------------------------------------

Maternal IgG levels in the serum of newborns generally match or exceed those in maternal serum (1,012 mg/mL IgG), and the half-life of maternal IgGs in infants is \>40 days ([@R60]). Thus, when a mother is seropositive for dengue viruses, maternal anti-dengue IgGs have the potential to modulate infant dengue infections for over 1 year after birth ([@R1]; [@R39]; [@R50]; [@R55]).

To define specific maternal anti-dengue IgG features that herald risk for infant dengue disease, we performed a global analysis of anti-dengue envelope (E) IgGs in mothers of infants with symptomatic (febrile) or asymptomatic primary dengue infections. To do this, we studied samples from a prospective cohort in San Pablo, Laguna, Philippines, a dengue-endemic region. After delivery, infants were followed rigorously for primary dengue infections, including documentation of subclinical infections evidenced by seroconversion ([@R14]; [@R34]).

Given the role of FcγRs in ADE of dengue virus infections, we first asked whether any maternal anti-E Fc glycosylation patterns could predict susceptibility to infant dengue disease. Characterization of anti-E IgG Fc glycoforms showed that mothers of infants who had clinically significant (symptomatic) primary dengue infections had significantly increased levels of afucosylated anti-E Fc glycoforms compared with mothers of infants who had asymptomatic primary infections ([Figure 1A](#F1){ref-type="fig"}). Indeed, ≥10% afucosylated Fc glycans was predictive of elevated risk for symptomatic infant dengue infections; this threshold predicted symptomatic infections in infants with a positive predictive value of 88%. Specificity of this marker was 93%, indicating that it nearly always predicted symptomatic dengue infections in infants. Sensitivity was lower, 46%, as many, but not all, symptomatic infections could be predicted using this serologic marker. Even omitting the sample with the highest level of afucosylation in the symptomatic group, the 10% threshold remained predictive with unchanged specificity (93%) and slightly reduced sensitivity (43%). Interestingly, this specific threshold of afucosylation was also identified in a prior study of hospitalized dengue patients; this prior study found that anti-E IgG with ≥10% afucosylated Fc glycans was predictive of the most severe disease outcomes during acute dengue infections that occurred in the presence of reactive, non-neutralizing IgGs ([@R59]). Aside from Fc fucosylation, other Fc glycoforms did not vary between mothers of infants with symptomatic and asymptomatic primary dengue infections ([Figure 1B](#F1){ref-type="fig"}).

Besides Fc glycosylation, the other features that can impact the A/I ratio of Fc-FcγR interactions were also measured. Extensive characterization of the maternal anti-E IgG response showed that symptomatic infant dengue infections could not be predicted by the IgG1/IgG2 ratio of anti-E subclasses, a measurement that accounts for the most abundant IgG subclasses, with IgG1 having increased affinity for activating FcγRs over IgG2 ([Figure 1C](#F1){ref-type="fig"}). The distribution of all maternal anti-E IgG sub-classes, the titer of anti-E IgGs, and the binding avidity of anti-E IgGs ([Figures 1D](#F1){ref-type="fig"}-[1F](#F1){ref-type="fig"}) were also not different between groups. In addition, there was no correlation between either symptomatic infant dengue infections or the levels of maternal anti-E afucosylation with infant sex, age at infection, days of fever during symptomatic infections, or serotype of the infecting dengue virus strain ([Table S1](#SD1){ref-type="supplementary-material"}). Because anti-NS1 IgGs can modulate the severity of dengue infections, we further assessed whether the maternal titer of anti-NS1 IgGs predicted symptomatic dengue infections in their infants and found no correlation ([Figure S1A](#SD1){ref-type="supplementary-material"}) ([@R26]; [@R29]). In addition, there was no significant difference in the abundance of anti-NS1 orto- tal IgG Fc fucosylation from mothers of infants with symptomatic or asymptomatic primary dengue infections ([Figure S1B](#SD1){ref-type="supplementary-material"}). The presence of ≥10% afucosylated glycans on anti-E IgG was the only factor identified in our characterizations that predicted risk for dengue disease in infants. Because Fc afucosylation increases affinity for FcγRIIIa, this finding pointed toward a role for FcγRIIIa in antibody-enhanced dengue infections.

FcγRUIa Signaling Is Driven by the Fucosylation Level in Dengue Immune Complexes and Enhances Dengue Virus Replication in Human U937 Monocytes {#S4}
----------------------------------------------------------------------------------------------------------------------------------------------

To study how FcγRIIIa signaling by dengue immune complexes might be impacted by variable levels of anti-E fucosylation, we used the maternal IgGs to generate dengue immune complexes and defined their signaling capacity in a FcγRIIIa reporter assay. This showed a linear correlation between endogenously produced levels of anti-E afucosylation and FcγRIIIa-mediated signaling ([Figure 2A](#F2){ref-type="fig"}). Next, we generated dengue virus immune complexes using pooled maternal IgGs with ≥10% or \<10% afucosylation of anti-E IgG; immune complexes with ≥10% afucosylation drove significantly higher FcγRIIIa signaling ([Figure 2B](#F2){ref-type="fig"}). To assess whether anti-E domain specificity might modulate FcγRIIIa signaling activity, we expressed monoclonal antibodies (mAbs) that bound to distinct domains of the E protein with fucosylated or afucosylated Fc glycans. All mAbs triggered significantly enhanced FcγRIIIa signaling when expressed with afucosylated Fc glycoforms regardless of their anti-E binding specificity ([Figure 2C](#F2){ref-type="fig"}; [Figure S2](#SD1){ref-type="supplementary-material"}; [Table S2](#SD1){ref-type="supplementary-material"}).

Although FcγRIIIa is present on macrophage and pro-inflammatory monocyte subsets that are associated with dengue disease, FcγRIIIa is not expressed on human monocytic or other granulocytic lineage cell lines that are often used to study ADE of dengue virus infections, such as THP-1, K562, or U937 cells ([@R21]; [@R56]; [@R57]). These cell lines express the high-affinity activating FcγR, FcγRI (except for K562 cells), along with the low-affinity FcγRs, activating FcγRIIa and inhibitory FcγRIIb. Further, primary cells and *in vivo* mouse models are not robust systems for studying the role of FcγRIIIa in dengue infections because FcγRIIIa is unstable on primary monocytes/macrophages that are cultured *ex vivo* ([@R40]; Wang lab, unpublished data), and mouse models that are humanized for FcγR expression, and thus express FcγRIIIa, are immunocompetent, rendering them incompatible with current dengue infection models ([@R51]; [@R63]). Thus, to dissect the role of FcγRIIIa in ADE of dengue infections, we generated human U937 monocytes expressing different combinations of the activating low-affinity FcγRs, FcγRIIa and FcγRIIIa ([Figures S3A](#SD1){ref-type="supplementary-material"}--[S3F](#SD1){ref-type="supplementary-material"}). FcγRIIa was previously shown to have a role in ADE of dengue infections ([@R8]), but a role for FcγRIIIa has not been defined.

First, U937 monocytes expressing different combinations of FcγRIIa and FcγRIIIa were infected with immune complexes made from dengue virus and five different maternal IgGs from the San Pablo cohort. Single-cycle infection was enhanced by up to 300% in monocytes expressing FcγRIIIa (FcγRIIa^+^FcγRIIIa^−^) compared with those expressing only FcγRIIa (FcγRIIa^+^FcγRIIIa^−^) ([Figure 3A](#F3){ref-type="fig"}). Next, we determined whether FcγRIIIa ITAM signaling was required for FcγRIIIa-mediated ADE, using cells expressing signaling-competent (FcγRIIa^+^FcγRIIIa^−^) or signaling-null \[FcγRIIa^+^FcγRIIIa^(ITAM--)^\] versions of FcγRIIIa ([Figure S3A](#SD1){ref-type="supplementary-material"}) ([@R6]). Interestingly, the FcγRIIIa-mediated enhancement of infection required ITAM signaling ([Figure 3A](#F3){ref-type="fig"}). To assess whether anti-E domain specificity might contribute to the involvement of FcγRIIIa in ADE, we tested the panel of afucosylated anti-E mAbs for their ability to modulate dengue infections. In all cases, anti-E mAbs mediated significantly increased infection in FcγRIIa^+^FcγRIIIa^+^ cells over U937 monocytes expressing only FcγRIIa. As observed with the maternal IgG, FcγRIIIa-mediated ADE required FcγRIIIa signaling in all cases ([Figure 3B](#F3){ref-type="fig"}). Overall, these studies showed that increasing the cellular A/I FcγR signaling ratio via FcγRIIIa ITAM signaling promoted ADE of dengue virus infections.

We next asked whether modulating cellular A/I FcγR signaling in parallel with dengue infection might impact ADE. Crosslinking individual FcγRs in FcγRIIa^+^FcγRIIIa^+^ U937 cells showed that increased signaling by the activating, ITAM-containing FcγRIIa or FcγRIIIa enhanced cell infectibility, whereas signaling through the inhibitory, ITIM-containing FcγRIIb reduced infection ([Figure 3C](#F3){ref-type="fig"}). These results are consistent with increased A/I signaling ratios promoting ADE of dengue infections, whereas reducing the A/I ratio via FcγRIIb signaling diminished ADE. Additive activating/ITAM signaling through crosslinking FcγRIIa and FcγRIIIa together resulted in the greatest enhancement of infection ([Figure 3D](#F3){ref-type="fig"}). These data supported a mechanism whereby infection was enhanced by cellular calcium flux, which is triggered by ITAM signaling ([@R7]; [@R27]). To verify this, we treated cells with the calcium ionophore, ionomycin, prior to infection. This treatment increased ADE of infection in a dose-dependent manner ([Figure 3E](#F3){ref-type="fig"}).

Having found that FcγRIIIa ITAM signaling could increase dengue infections, we next sought to determine whether FcγRIIIa might have a separate role in mediating attachment of dengue immune complexes. To investigate this, we used well-characterized blocking mAbs against FcγRI, FcγRIIa, or FcγRIIIa to prevent immune complex attachment to cells prior to infection ([@R9]; [@R21]; [@R37]; [@R53]; [@R62]). In FcγRIIa^+^ FcγRIIIa^+^ U937 cells, blocking either FcγRI or FcγRIIa during immune complex attachment prevented ∼50% infection, whereas blocking FcγRIIIa alone with the blocking mAb, 3G8, did not inhibit infection ([Figure 4A](#F4){ref-type="fig"}) ([@R9]; [@R21]; [@R37]; [@R53]; [@R62]). Combining blocking mAbs for FcgRI and FcgRIIa inhibited infection by ∼80%, and inclusion of the FcγRIIIa blocking mAb did not further diminish infection. In freshly isolated primary monocytes, blocking attachment of immune complexes to FcγRIIa prior to entry prevented nearly all infection, whereas blocking FcγRI, FcγRIIb, or FcgRIIIa did not reduce infection ([Figure 4B](#F4){ref-type="fig"}). These results are consistent with studies showing that FcγRIIa on monocytes mediates dengue immune complex attachment and entry ([@R8]; [@R32]; [@R35]) and suggested that the FcγRIIIa-mediated enhancement is due to modulation of a post-attachment step of infection.

Inhibitors of the Calcineurin Signaling Network Block Dengue Virus Replication {#S5}
------------------------------------------------------------------------------

Engagement and crosslinking of the activating FcγRs trigger phosphorylation of ITAM domains by Src family kinases and intracellular calcium flux ([@R10]; [@R27]). Calcium flux, in turn, activates calcineurin, a serine/threonine phosphatase that recognizes a host of substrates, scaffolds, and regulator proteins through specific docking motifs ([@R46]; [@R47]). To dissect how enhanced A/I ratios contribute to ADE of dengue infections, we treated cells with inhibitors of the ITAM signaling pathway prior to infection. First, FcγRIIa^+^FcγRIIIa^+^ monocytes were treated with PRT, an inhibitor of Syk tyrosine kinase activity, required for initiation of ITAM signaling ([@R36]; [@R43]). This inhibited dengue infection ([Figure 5A](#F5){ref-type="fig"}), supporting the requirement for ITAM signaling in ADE of dengue virus infection.

Next, we tested the hypothesis that ADE of dengue infection is enhanced by calcium flux via the calcineurin signaling network. The small-molecule inhibitor INCA-6 ([@R12]) and the peptide inhibitor 11R-VIVIT (VIVIT) ([@R4]) act selectively to prevent the association of calcineurin with substrates that bind via the calcineurin PxIxIT docking motif ([@R47]). Both inhibitors prevented dengue virus infection in U937 monocytes ([Figures 5B](#F5){ref-type="fig"} and [5C](#F5){ref-type="fig"}). Inhibitors were used at concentrations that did not impact cell viability ([Figure S4](#SD1){ref-type="supplementary-material"}). To assess the specificity of this observation for dengue infections, we studied the impact of the VIVIT inhibitor on infection of U937 cells by influenza A viruses. Although dengue serotypes 2 and 3 were robustly inhibited by VIVIT, influenza A viruses (H1N1 A/Netherlands/602/2019 and H3N2 A/HK/1/1968 strains) were not affected by this inhibitor of the calcineurin signaling network ([Figure 5D](#F5){ref-type="fig"}). We next treated cells with the VIVIT inhibitor during or at different time points after dengue infection to characterize the kinetics of the required calcineurin network activity. Treatment of cells up to 6 h after entry significantly reduced infection, consistent with disruption of a post-entry stage of infection ([Figure 5E](#F5){ref-type="fig"}). Interestingly, FK506 and cyclosporin A, two clinically used drugs that block calcineurin through mechanisms distinct from INCA-6 and VIVIT ([@R28]), did not prevent dengue infections ([Figure S5](#SD1){ref-type="supplementary-material"}). These studies show that calcineurin-PxIxIT site interactions are required for maximal dengue virus infections, suggesting new clinical strategies for treatment of dengue infections.

IgG Fucosylation Is Stable over Time, Suggesting Utility as a Predictive Marker for Dengue Disease Risk {#S6}
-------------------------------------------------------------------------------------------------------

To be a useful marker of dengue disease susceptibility, the abundance of Fc afucosylation would have to be stable over time and withstand immune perturbation. To assess stability of this IgG modification, we performed a longitudinal study of IgGs from healthy adults in a North American cohort who were challenged with influenza A virus ([@R38]). We characterized IgG afucosylation prior to and over a period of 60 days after influenza virus challenge. The abundance of afucosylated glycans was remarkably durable over this period and, despite virus challenge ([Figure S6](#SD1){ref-type="supplementary-material"}), supporting utility of this serologic marker to guide clinical care of dengue patients.

DISCUSSION {#S7}
==========

Here, we show that elevated afucosylated Fc glycans (≥ 10%) on maternal anti-E IgGs is one risk factor for susceptibility of infants to disease during primary dengue virus infections. Mechanistic studies performed to identify how afucosylated anti-E IgGs can impact dengue infections support a model whereby the presence of afucosylated dengue immune complexes triggers a FcγRIIIa-modulated infection characterized by increased ITAM signaling. Enhanced ITAM signaling, in turn, promoted dengue infections in U937 monocytes through an intrinsic ADE mechanism ([Figure 5F](#F5){ref-type="fig"}) ([@R25]). On a cellular level, the data show a role for FcγRIIIa in enhancing ADE of dengue virus infections through cooperativity with FcγRIIa. Although FcγRIIa acts in virus immune-complex attachment and entry (extrinsic ADE) ([@R25]), we show that the increased cellular A/I signaling ratio triggered by afucosylated immune complex-FcγRIIIa interactions supports dengue virus infection through calcineurin signaling network interactions requiring the PxIxIT docking motif ([Figure 5G](#F5){ref-type="fig"}). This mechanism suggests novel treatment strategies for dengue infections that target this pathway.

An important topic for future studies on the pathogenesis of dengue disease is the cellular activities associated with afucosylated IgGs during dengue infection that were not studied here. We have used percent infection as the readout of activity conferred by anti-dengue Fc afucosylation and of FcγRIIIa signaling in ADE of dengue virus infections, yet FcγRIIIa signaling activity likely impacts disease pathogenesis through multiple mechanisms, including modulation of cytokine production by FcγRIIIa-expressing cells.

Because mortality rates in severe dengue cases can be nearly eliminated with intensive clinical monitoring ([@R2]; [@R22]), identifying markers for susceptibility to dengue disease could dramatically improve the clinical management of dengue patients. Here we show that maternal IgG Fc fucosylation could be used in the cohort studied to identify a significant subset of susceptible infants. Prospective cohort studies are now needed to examine testing of antibody fucosylation to guide the treatment of primary infant dengue infections and acute dengue infections in non-infant populations.

STAR★METHODS {#S8}
============

Detailed methods are provided in the online version of this paper and include the following:

KEY RESOURCES TABLE {#S9}
-------------------

  REAGENT or RESOURCE                                                                                                                                            SOURCE                                         IDENTIFIER
  -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------------------------------------
  Antibodies                                                                                                                                                                                                    
  FITC conjugated anti-human FcγRIIa, clone IV.3                                                                                                                 STEMCELL Technologies                          Cat\#60012FI; RRID: AB_2722545
  Brilliant Violet 711 conjugated anti-human FcγRIIIa, clone 3G8                                                                                                 Biolegend                                      Cat\#302044; RRID: AB_2563802
  Anti-human FcγRIIb, clone 2B6                                                                                                                                  J. Ravetch, Rockefeller University             N/A
  APC anti-human FcγRI, clone 10.1                                                                                                                               Biolegend                                      Cat\#305014; RRID: AB_1595428
  Influenza A NP Monoclonal Antibody (D67J), FITC                                                                                                                Invitrogen                                     Cat\#MA17322; RRID: AB_1017747
  anti-E antibody, clone D1-4G2-4-15                                                                                                                             ATCC                                           Cat\#VR-1852; RRID: AB_827205
  Fucosylated and afucosylated human monoclonal antibody 23-5G2D2747(4)                                                                                          ([@R49])                                       N/A
  Fucosylated and afucosylated human monoclonal antibody B7                                                                                                      ([@R45])                                       N/A
  Fucosylated and afucosylated human monoclonal antibody 2D22                                                                                                    ([@R16])                                       N/A
  Fucosylated and afucosylated human monoclonal antibody 753(3) C10                                                                                              ([@R45])                                       N/A
  Fucosylated and afucosylated human monoclonal antibody 5J7                                                                                                     ([@R16])                                       N/A
  anti- FcγRIIIa, clone 3G8                                                                                                                                      Biolegend                                      Cat\#302057; RRID: AB_2572005
  anti-FcγRIIa clone IV.3                                                                                                                                        Stem Cell Technology                           Cat\#60012; RRID: AB_2722545
  Bacterial and Virus Strains                                                                                                                                                                                   
  DENV2 New Guinea C                                                                                                                                             BEI Resources                                  NR-84
  A/Hong Kong/1/1968, H3N2                                                                                                                                       BEI Resources                                  NR-28620
  A/Netherlands/602/2009, H1N1                                                                                                                                   Wang Lab Stock                                 N/A
  DENV3 C0360/94                                                                                                                                                 BEI Resources                                  NR-48800
  Biological Samples                                                                                                                                                                                            
  Sera collected at birth from 29 dengue seropositive mothers of infants who had primary dengue infections                                                       ([@R34])                                       [ClinicalTrials.gov](ClinicalTrials.gov): NCT00377754
  Sera from 8 individuals challenged with Ca/04/2009/H1N1 Vero Grown Virus. Sera were collected prior to challenge as well as on day 30 and 60 post-challenge.   ([@R38])                                       [ClinicalTrials.gov](ClinicalTrials.gov): NCT01646138
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                 
  Dengue Envelope Protein Serotype 1                                                                                                                             Prospec                                        DEN-021
  Dengue Envelope Protein Serotype 2                                                                                                                             Prospec                                        DEN-022
  Dengue Envelope Protein Serotype 3                                                                                                                             Prospec                                        DEN-023
  Dengue Envelope Protein Serotype 4                                                                                                                             Prospec                                        DEN-024
  11R-VEET                                                                                                                                                       Thermo Fisher                                  Cat\#CM102281.2
  11R-VIVIT                                                                                                                                                      Thermo Fisher                                  Cat\#CM102281.1
  INCA-6                                                                                                                                                         Abcam                                          Cat\#ab145864
  PRT062607                                                                                                                                                      Fisher Scientific                              Cat\#NC0664362
  Ionomycin                                                                                                                                                      Invivogen                                      Cat\#inh-ion
  2F-Peracetyl-Fucose                                                                                                                                            EMD Millipore                                  Cat\#344827
  Critical Commercial Assays                                                                                                                                                                                    
  Protein G Sepharose 4 Fast Flow resin                                                                                                                          GE Healthcare                                  Cat\#17061802
  NHS agarose resin                                                                                                                                              ThermoFisher                                   Cat\#26196
  Experimental Models: Cell Lines                                                                                                                                                                               
  FcγRIIa^+^FcγRIIIa^+^ U937 Cells                                                                                                                               This paper                                     N/A
  FcγRIIa^−^FcγRIIIa^−^ U937 Cells                                                                                                                               This paper                                     N/A
  FcγRIIa^+^FcγRIIIa^(ITAM−/−)^ U937 Cells                                                                                                                       This paper                                     N/A
  U937 Cells                                                                                                                                                     ATCC                                           CRL-1593.2
  Vero cells                                                                                                                                                     ATCC                                           CCCL-81
  Expi293 cells                                                                                                                                                  ThermoFisher                                   Cat\#A14527
  Recombinant DNA                                                                                                                                                                                               
  pLJM1-EGFP plasmid                                                                                                                                             Addgene                                        Plasmid \#19319
  Human codon optimized cas9 DNA                                                                                                                                 Addgene                                        Plasmid \#41815
  Software and Algorithms                                                                                                                                                                                       
  GraphPad PRISM 9                                                                                                                                               GraphPad Software, La Jolla, California, USA   <https://www.graphpad.com>
  Flowjo                                                                                                                                                         FlowJo,LLC                                     <https://www.flowjo.com/>
  Analyst 1.6.1 software                                                                                                                                         SCIEX                                          <https://sciex.com>
  MultiQuant 2.1.1                                                                                                                                               SCIEX                                          <https://sciex.com>

RESOURCE AVAILABILITY {#S10}
---------------------

### Lead Contact {#S11}

The lead contact for this study is Taia T. Wang (<taiawang@stanford.edu>).

### Materials Availability {#S12}

This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact.

### Data and Code Availability {#S13}

This study did not generate any unique datasets or code. An unpaired Student's t test was utilized to calculate p value: \*p \<0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

### Key Resources Table {#S14}

See attached file

Experimental Model And Subject Details {#S15}
--------------------------------------

Clinical cohorts and samples: Samples from mothers of infants who had primary dengue infections were from a study that was approved by the institutional review boards of the Research Institute for Tropical Medicine, Philippines, and the University of Massachusetts Medical School. Mothers and their healthy infants were recruited and enrolled after providing written informed consent ([ClinicalTrials.gov](ClinicalTrials.gov) NCT00377754) ([@R34]). Symptomatic dengue was defined as febrile illness with a positive result by dengue serotype-specific reverse-transcription PCR in acute phase sera ([@R33]). Clinically inapparent dengue infection (asymptomatic infection) was determined using a hemagglutination inhibition assay (HAI assay); a ≥ four-fold increase in HAI against one or more dengue serotypes in the absence of febrile illness confirmed asymptomatic infection ([@R34]). The outcome assessed was clinical phenotype during dengue virus infection (symptomatic infection versus asymptomatic infection) ([Table S1](#SD1){ref-type="supplementary-material"}). Samples from the controlled influenza A virus challenge study have been previously described ([@R38]). The study ([ClinicalTrials.gov](ClinicalTrials.gov) NCT01646138) was approved by the National Institute of Allergy and Infectious Diseases institutional review board and underwent an ethics review by the NIH Department of Bioethics prior to being conducted. The study was conducted in accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.

METHOD DETAILS {#S16}
--------------

IgG Fc glycan and IgG subclass analysis: Methods for relative quantification of Fc Glycans and IgG subclasses have been previously described ([@R58]; [@R59]). Briefly, IgGs were isolated from serum by protein G purification. Antigen-specific IgGs were isolated on NHS agarose resin (ThermoFisher; 26196) coupled to the protein of interest. Mixed envelope proteins from the four DENV serotypes were used (ProSpec; DEN-021, DEN-022, DEN-023, DEN-024). Following tryptic digestion of purified IgG bound to antigen-coated beads, nanoLC-MS/MS analysis for characterization of glycosylation sites was performed on an Ulti-Mate3000 nanoLC (Dionex) coupled with a hybrid triple quadrupole linear ion trap mass spectrometer, the 4000 Q Trap (SCIEX). MS data acquisition was performed using Analyst 1.6.1 software (SCIEX) for precursor ion scan triggered information dependent acquisition (IDA) analysis for initial discovery-based identification.

For quantitative analysis of the glycoforms at the N297 site across the three IgG subclasses (IgG1, IgG2 and IgG3/G4), multiple-reaction monitoring (MRM) analysis for selected target glycopeptides, was applied using the nanoLC-4000 Q Trap platform to the samples which had been digested with trypsin. The m/z of 4-charged ions for all different glycoforms as Q1 and the fragment ion at m/z 366.1 as Q3 for each of transition pairs were used for MRM assays. A native IgGs tryptic peptide (131-GTLVTVSSASTK-142) with transition pair of, 575.9^+2^/780.4 was used as a reference peptide for normalization. IgG subclass distribution was quantitatively determined by nanoLC-MRM analysis of tryptic peptides following removal of glycans from purified IgGs with PNGase F. Here the m/z value of fragment ions for monitoring transition pairs was always larger than that of their precursor ions to enhance the selectivity for unmodified targeted peptides and the reference peptide. All raw MRM data were processed using MultiQuant 2.1.1 (SCIEX). All MRM peak areas were automatically integrated and inspected manually. In the case where the automatic peak integration by MultiQuant failed, manual integration was performed using the MultiQuant software.

U937 cell lines: Wild-type U937 cells are FcγRIIa^+^FcγRIIIa^-^; FcγRIIa was deleted from the wild-type line using CRISPR/Cas9 methods to generate FcγRIIa^-^FcγRIIIa^-^ monocytes. Wild-type cells were stably transfected for expression of FcγRIIIa generating the FcγRIIa^+^FcγRIIIa^+^. A final cell line, FcγRIIa^+^FcγRIIIa^(ITAM--/--)^, expresses FcγRIIa and a variant of FcγRIIIa that does not associate with the Fc receptor gamma chain, and thus lacks ITAM signaling ([@R6]).

The gRNAs to target FcγRIIa were designed utilizing DESKGEN software, and inserted into sequence containing U6 promoter and gRNA scaffold ([@R61]). The gRNA sequence to target human FcγRIIa was 5′GATGTATGTCCCAGAAACCTG3′. The final fragment (Integrated DNA Technologies) was cloned into the pCR-BluntII-Topo vector. Human codon optimized cas9 DNA was obtained from (Addgene, Plasmid \#41815). To generate the knockout cell line, U937 cells were transfected with 1.5μg hCas9 and 0.5μg of gRNA via electroporation. The U937 cells were electroporated using Lonza Nucleofector 2b (program W-001) and the Nucleofection Kit C (Lonza, VPA-1004). After electroporation, U937 cells were incubated at 37°C for 48 hours. Following incubation, cells were synchronized at the early S phase using a double thymidine block. The cells were stained with IV.3-FITC, and FcγRIIa negative cells were bulk sorted on SH800 sorter. After one bulk sort, the cells were single cell sorted based on negative FcγRIIa expression. To generate FcγRIIIa^+^ cells, the wild-type cells were nucleofected with pLJM1-EGFP plasmid (Addgene, Plasmid \#19319) that has EGFP replaced with FcγRIIIa or FcγRIIIa^(ITAM--/--)^, while the FcγRIIa^-^ cells were nucleofected with pLJMI-FcγRIIIa only. Stably transfected clones were selected using 1ug/mL puromycin.

FcγRIIIa signaling assay: U937 cells were infected with DENV2 New Guinea C (BEI Resources; NR-84) at MOI2 and 0.2ug/ml 235WT. 48h post infection, cells were washed once with PBS. Infected U937 cells were added to anti-dengue mAbs or purified maternal IgGs. Infected U937 cell immune complexes were washed and added to 100ul of Jurkat-Lucia NFAT CD16 (Invivogen; jktl-nfat-cd16) cell suspension at a concentration 1×10^6^cells/ml in IMID media and incubated at 37°C for 24h. 20ul of assay supernatant was then transferred to a 96-well white polystyrene clear flat bottom plate. 50ul Lucia detection medium QUANTI-Luc (Invivogen; rep-qlc1) was added and luciferase activity was measures using Tecan Infinite M100 with a 0.1 s reading time.

FACS staining of U937 cell lines: U937 cell lines were stained with a fixable live/dead stain (ThermoFisher; L10119). To assess FcγR expression cells were stained at 1:100 with a FITC conjugated anti-human FcγRIIa antibody, clone IV.3 (STEMCELL Technologies; 60012FI); Brilliant Violet 711 conjugated anti-human FcγRIII, clone 3G8 (Biolegend; 302044); an FcγRIIb antibody clone 2B6 (gifted by the Ravetch lab, Rockefeller University) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) and an APC conjugated anti-human FcγRI, clone 10.1 (Biolegend, 305014) for 30 minutes at 4°C.

Cross-linking of FcγRs for receptor signaling detection: U937 cell lines were treated with mouse anti-FcγRIIIa/b, clone 3G8 (Biolegend; 302057) at 10μg/ml in Optimem on ice for 30 min. Anti-mouse Fc was then added at 1.25μg per 1 million cells and incubated at 37°C for 3 min to crosslink mAb 3G8. Cells were then lysed in a one to one ratio of cell lysate buffer containing 100mM TRIS-HCL/300mM NaCL/2% Triton X-100 and a protease/phosphatase inhibitor cocktail (ThemoFisher; 88668). Protein concentrations were quantified using BCA Protein Assay Kit (ThermoFisher; 23227) and lysates were treated by boiling for 5 min with Laemmli SDS sample buffer containing 5% β-mercaptoethanol. Cell lysates were run on Mini-PROTEAN® TGX Precast Protein Gels (Bio Rad; 456903). Blots were blocked 5% BSA in TBS buffer 20mM Tris-HCL/150mM NaCl pH 7.6 for 2 hours and were subsequently incubated with anti-phosphotyrosine secondary antibody (Biolegend; 309302) at 1:1,000 in 5% BSA in TBS, 0.2% Tween-20 (TBST) overnight at 4 °C. Blots were washed and incubated with anti-mouse IgG Fc-HRP (Southern Biotech; 1030--05) at 1:10,000 for 1 hour at room temperature. Blots were developed with Western Lightning ECL Pro (Perkin Elmer; NEL120001EA) according to manufacturer's instructions. The membrane was imaged using the Amersham Imager 600 (GE Life Sciences) with auto exposure under chemiluminescent detection settings. Post-imaging, the membrane was washed extensively with TBST before treating with Restore^™^ Western Blot Stripping Buffer (ThermoFisher; 21059) for 15 min at room temperature. To analyze protein loading, the membrane was re-blocked with 5% BSA in TBST for 2 hour at room temperature before probing with a 1:200 dilution anti-vinculin 7F9 (Santa Cruz Biotechnology; sc-73614) in 5% BSA/TBST for 1 hour at room temperature followed by anti-mouse IgG HRP secondary, as above. The membrane was then treated with chemiluminescent substrate and imaged as described above.

Cross-linking of FcγRs in parallel with infection: Non-TC treated round bottom plates were coated with FcγR specific antibodies in PBS for 1h at 37°C. Coating antibodies: anti-FcγRIIa clone IV.3 (Stem Cell Technology; 60012) (at 5ug/ml individually or 2.5ug/ml in conjunction with other antibodies), anti-FcγRIIb clone 2B6 (generously provided by J. Ravetch, Rockefeller University) (at 5ug/ml individually or 2.5ug/ml in conjunction with other antibodies); and anti- FcγRIIIa, clone 3G8 (Biolegend; 302057) (at 10ug/ml individually or 5ug/ml in conjunction with other antibodies). Plates were coated at 10ug/ml in PBS of human IgG2/kappa (Sigma Aldrich; AG504) to control for protein coat. Plates were washed twice and 50,000 FcγRIIa^+^FcγRIIIa^+^ U937 cells/well diluted in OPTI-MEM were added to plate and incubated at 4°C for 30min. Immune complexes composed of DENV2 New Guinea C (BEI Resources; NR-84) and 0.2ug/ml mAb 235 were then added to plate and incubated at 37°C for 2h. Cells were washed twice in PBS and re-suspended in OPTI-MEM followed by an incubation for 22 h at 37°C. Percent infection was detected by FACs.

Monoclonal antibody production: Antibodies: 23--5G2D2747(4)([@R49]), B7 (B7)([@R17]; [@R45]; [@R52]), 2D22([@R16]; [@R19]; [@R52]), and 753(3) C10 (C10)([@R45]; [@R52]), 752--2 C8([@R16]; [@R45]; [@R52]), and 5J7([@R16]; [@R20]; [@R52]) were expressed in Expi293 cells as follows. For afucosylated variants, Expi293 cells (ThermoFisher; A14527) were split to 2.0 × 10^6^cells/mL in a 10 mL volume 24h prior to transfection and treated with 100 μM of afucosyl transferase inhibitor, 2F-Peracetyl-Fucose ([@R44]) (EMD Millipore, 344827). On the day of transfection, 5 μg filter-sterilized DNA (2.5 μg each of heavy and light chain-encoding plasmids) was added to 1mL of Expi293 medium (ThermoFisher Scientific; A1435101) in a fresh tube, and mixed. To this, 13 μL (1.3 μL/mL of total transfection volume) of FectPro transfection Reagent (Polyplus Transfection; 116--001) was added. The DNA-transfection reagent mixture was incubated at room temperature for 10 minutes before adding dropwise to 10 mL of the Expi293 cells. The cells were then additionally treated with a final concentration of 4g/L glucose and 3 mM valproic acid. The cells were then grown under shaking conditions (125 rpm) at 37°C for 3 days before receiving an additional 4g/L final concentration of glucose. The cells were harvested on day 6 post-transfection, the cell pellet discarded, and the supernatant media filtered before purification. MAbs were purified over Protein G Sepharose 4 Fast Flow resin (GE Healthcare; 17061802). The antibodies were buffer exchanged into PBS pH 7.4 prior to use in any cell-based assays.

Cell-based ELISA: Wells of a 96 well plate were seeded with 3×10^4^ Vero cells (ATCC; CCL-81). The next day cells were infected with DENV2 New Guinea C (BEI Resources; NR-84) or DENV3 C0360/94 (BEI Resources; NR-48800) MO11 for 1 hour, washed, and incubated for 48 h in MEM, 1% methylcellulose, 2% inactivated FBS, antibiotics, and L-glutamine. Cells were fixed with 4% formaldehyde for 30 minutes and permeabilized in 2% inactivated FBS/0.1% saponin/PBS. For analysis of clinical samples, serially diluted maternal sera were incubated for 2 hours at room temperature on cells infected with the virus serotype of the paired infant's dengue virus infection. For mAb binding assays, mAbs were titrated and incubated for 2 hours at room temperature on DENV2 infected cells. Cells were washed with PBS--0.1% Tween 20 and incubated with mouse anti-human IgG Fc-HRP (Southern Biotech; 9040--05) for 1 hour. Following incubation, the wells were washed and TMB Liquid Substrate (Sigma; T0440) was added and stopped with 1M HCL after approximately 5 minutes. Absorbance at 450 nm was measured; ELISA performed in triplicate.

Antibody-dependent infections: Anti-E mAbs were incubated with dengue viruses for 30 minutes at 37°C to form immune complexes. Afucosylated anti-E mAbs were used where indicated in the text. 5×10^4^ U937 cells were added to the immune complexes (MOI: 4) in RPMI containing 2% heat-inactivated FBS, antibiotics, MEM nonessential amino acid solution, 2-mercaptoethanol, and HEPES. Cells were infected for 2 hours at 37°C, washed, then resuspended in infection media and incubated for an additional 4--24 h at 37°C. Infected cells were stained with a fixable violet live/dead stain (ThermoFisher; L34955)for30 min, fixed with 4% form-aldehyde and permeabilized in 2% inactivated FBS, 5mM EDTA, 0.1% saponin in PBS. Cells were stained using an anti-E antibody, clone 4G2 (ATCC; VR-1852) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) at 1:400 for 30min. The frequency of infected cells was determined using flow cytometry, defined as the percentage of live, single cells that were positive for mAb 4G2 staining. For infections involving inhibitors or activators of ITAM signaling, U937s were treated with titrated inhibitors/activators: Ionomycin (Invivogen; inh-ion), PRT062607 (Fisher Scientific; NC0664362), INCA-6 (Abcam; ab145864), 11R-VIVIT (Thermo Fisher; CM102281.1), or 11R-VEET (Thermo Fisher; CM102281.2) in complete RPMI media for 1h-6h at 37C prior to, during or following infection as indicated. Immune complexes were formed at 37°C for 30min between hIgG1 mAb 235 and DV2 (MOI4) at 37°C. U937 were washed 2 times with PBS and then added to the immune complexes for a 2h infection at 37°C. Cells were then washed 2xin PBS and re-suspended in infection media followed by incubation for an additional 22 h at 37°C.

FcγR blocking assay: Afucosylated anti-E monoclonal antibody 235 expressed as a human IgG1 (hIgG1) was incubated with dengue virus for 30 minutes at 37°C to form immune complexes and then cooled on ice for 15 min. FcγRIIa^+^FcγRIIIa^+^ U937 cells or CD14+ PBMCs were incubated on ice for 30 minutes with different combinations of FcγR-specific blocking antibodies, described above, each at 4ug/ml([@R9]; [@R21]; [@R62]). Total antibody concentration between determinants was controlled by addition of human IgG2/kappa where needed (Sigma Aldrich; AG504). Cells were washed with ice-cold PBS and added to dengue immune complexes (MOI 5). Infection proceeded for 1 hour on ice. Cells were then washed and resuspended in infection media followed by incubation for an additional 22 h at 37°C. Percent infection was determined by FACs.

Influenza infections of U937 cells: Influenza viruses A/Hong Kong/1/1968, H3N2 (BEI; NR-28620) and A/Netherlands/602/2009, H1N1 in Opti-MEM were added to FcγRIIa+ FcγRIIIa+ U937 cells for 2h at 37°C. Cells were then washed twice with PBS, resuspended in OPTI-MEM and incubated at 37°C for an additional 22h. Percent infection was determined by FACs. Influenza-infected cells were detected using Alexa488 influenza A NP monoclonal antibody clone D67J (Invitrogen; MA1--7322) at a 1:100 dilution. For infections involving inhibitors of ITAM signaling, U937s were treated with titrated inhibitors: 11R-VIVIT (Thermo Fisher; CM102281.1) or 11R-VEET (Thermo Fisher; CM102281.2) in complete RPMI media for 2h at 37°C prior to infection. Treated cells were washed 2x with PBS before being added to virus.

Avidity ELISA: The avidity ELISA has been described before ([@R58]). Briefly, Wells of microtiter plates were coated with DENV2 (ProSpec; DEN-022) or DENV3 (ProSpec; DEN-023) E proteins (2.5μg mr^--1^ in PBS) for 2 hours at 37°C. Plates were blocked for 30 min with 1% BSA/1%PBS and then incubated with titrated Gentle Ag/Ab Elution Buffer, pH 6.6 (ThermoFisher; 21027) and maternal IgG, which was normalized for optical density of binding to dengue-infected cells and matched for virus serotype of the paired infant's dengue virus infection. Plates were washed with PBS/0.1% Tween 20 and wells were incubated with alkaline phosphatase-conjugated anti-human Fc (Southern Biotech; P7998) followed by 2 hour incubation. Following incubation, the wells were washed and p-nitrophenyl phosphate substrate solution (Sigma; P7998) was solution was added. Absorbance at 405 nm was measured after approximately 45 min; ELISA performed in triplicate.

Western blot of mAbs: Antibodies were run under reducing and denaturing conditions by SDS-PAGE on a gradient gel with Tris-Glycine buffer. The gel was transferred to a 0.45 μm nitrocellulose membrane (Bio-Rad) using semi-dry transfer. The membrane was blocked in 5% BSA in TBST for 2 hours at room temperature, before probing with a 1:10,000 dilution of biotinylated Aleuria Aurantia Lectin or AAL (Vector Labs; B-1395) in 5% BSA/TBST for 1 hour at room temperature. After 4--6 washes with TBST, the membrane was incubated with a 1: 2500 dilution of streptavidin-HRP (Southern Biotech; 7100--05) in 5% BSA/TBST for 1 hour at room temperature. After 4--6 washes with TBST the membrane was treated with chemiluminescent substrate Western Lightning ECL Pro (Perkin Elmer; NEL120001EA) according to manufacturer's instructions. The membrane was then imaged using the Amersham Imager 600 (GE Life Sciences) with auto exposure under chemiluminescent detection settings. Post-imaging, the membrane was washed extensively with TBST before treating with Restore™ Western Blot Stripping Buffer (ThermoFisher; 21059) for 15 min at room temperature. To analyze protein loading, the membrane was re-blocked with 5% BSA in TBST for 2 hours at room temperature before probing with 1:5000 dilution of anti-human IgG-HRP (Southern Biotech) in 5% BSA/TBST for 1 hour at room temperature. The membrane was then treated with chemiluminescent substrate, and imaged as described above.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S17}
---------------------------------------

All *in vitro* experiments were performed using three different biological replicates at least three independent times. Normality of Fc glycan distribution was confirmed by Kolmogorov-Smirnov test. Statistical analysis was performed with an unpaired t test. All the analyses were performed using the GraphPad Prism 9 software (Graphpad Software, San Diego, California, USA).
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![Maternal Anti-E IgG Characterization\
Anti-E Fc glycoforms were characterized.\
(A) Fucosylation of Fc glycoforms was significantly different in abundance between mothers of infants with symptomatic (red) and asymptomatic (black) dengue infections, with afucosylated Fc glycans significantly increased in mothers of infants with symptomatic dengue infections. ≥10% afucosylated Fc glycans was predictive of elevated risk for symptomatic infant dengue infections with a positive predictive value of 88%.\
(B) No significant differences in other Fc glycoforms, bisected (N), galactosylated (G), or sialylated (S), were observed.\
(C--F) There were also no differences in the maternal anti-E (C) IgG1/IgG2 subclass ratio, (D) IgG subclass distribution, (E) IgG titer on dengue-infected cells, or (F) IgG avidity between mothers of infants who developed symptomatic or asymptomatic primary dengue infections.\
Each symbol (A--F) represents an individual donor. Data are representative of one experiment per donor (A--D) or three experiments (E and F); (A--C and F) horizontal bars represent mean of clinical samples. Significance was assessed by unpaired Student's t test, where p \< 0.05 was considered significant; \*p \< 0.05.](nihms-1593932-f0002){#F1}

![Anti-E Fucosylation in Dengue Virus Immune Complexes Determines FcγRIIIa Signaling by Effector Cells\
Dengue immune complexes were generated from maternal serum IgGs.\
(A) FcγRIIIa signaling was linearly correlated with the abundance of afucosylated Fc glycoforms of anti-DENV E IgGs within immune complexes, n = 29.\
(B) Dengue immune complexes generated from pooled maternal IgGs with ≥ 10% anti-E afucosylation triggered significantly more FcγRIIIa signaling when compared with immune complexes generated from pooled maternal IgGs with \<10% anti-E afucosylation. Both pools were generated from sera of mothers of infants who experienced symptomatic primary dengue infections.\
(C) Fucosylation of distinct anti-E mAbs modulates FcγRIIIa signaling. Fucosylated (black circles) or afucosylated (white circles) anti-DENV E mAbs with distinct Fab specificities were tested for the ability to trigger FcγRIIIa signaling. Enhanced FcγRIIIa signaling by afucosylated immune complexes was observed in all cases. GRLR is a non-FcγR-binding Fc variant.\
Each point in (A) represents an individual donor. Data shown in (B) and (C) are representative of three experiments. \*p\<0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001 (unpaired Student's t test). Data in (A)--(C) are representative of a minimum of three experiments. Error bars (B and C) represent the standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol marking the data point.](nihms-1593932-f0003){#F2}

![FcγRIIIa Signaling Enhances Antibody-Dependent Infection of U937 Monocytes\
(A) Infection by dengue immune complexes generated with maternal IgGs was significantly enhanced in FcγRIIIa^**+**^ monocytes, and FcγRIIIa signaling was required for enhancement in all cases. Red line: FcγRIIa^**+**^FcγRIIIa^**+**^ cells; black line: FcγRIIa+FcγRIIIa^**−**^ cells; broken red line, unfilled circles: FcγRIIa^**+**^FcγRIIIa^**(ITAM--)**^ cells.\
(B) The role of FcγRIIIa signaling in ADE was evaluated by comparison of infection in FcγRIIa^**+**^FcγRIIIa^**+**^ cells (red), FcγRIIIa-signaling null FcγRIIa^**+**^FcγRIIIa^**(ITAM--)**^ cells (white), and FcγRIIa+FcγRIIIa^**−**^ (black) or FcγRIIa^**−**^FcγRIIIa^**−**^ (blue) cells. Immune complexes were generated from dengue virus and afucosylated anti-envelope mAbs 235, B7, 2D22, or C10, which have distinct anti-E binding specificities. In all cases, FcγRIIIa signaling was required for maximal infection.\
(C) Signaling induced by crosslinking of FcγRIIa or FcγRIIIa promoted infection of FcγRIIa^**+**^FcγRIIIa^**+**^ U937 cells, whereas crosslinking the inhibitory FcγR, FcγRIIb, reduced infectibility of cells.\
(D) Combined signaling by activating FcγRIIa and FcγRIIIa during infection resulted in maximal infectibility of FcγRIIa^**+**^FcγRIIIa^**+**^ U937 cells.\
(E) Increasing cellular calcium flux promoted infection of FcγRIIa^**+**^FcγRIIIa^**+**^ U937 cells.\
\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*p \< 0.0001 (unpaired Student's t test). Data are representative of a minimum of three experiments. Error bars represent the standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol marking the data point.](nihms-1593932-f0004){#F3}

![FcγRIIIa Does Not Mediate Virus Immune Complex Attachment during ADE in Monocytes\
(A) Individual or combined FcγRs were blocked during the viral attachment step of infection in FcγRIIa^**+**^ FcγRIIIa^**+**^ U937 monocytes. Blocking FcγRIla and/or FcγRI during immune complex attachment significantly reduced infection, whereas blocking FcγRIIIa did not impact infection.\
(B) Blocking FcγRIIa alone during attachment in primary monocytes prevented their infection, whereas blocking FcγRI, FcγRIIb, or FcγRIIIa did not impact infection.\
\*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001 (unpaired Student's t test). Data are representative of a minimum of three experiments. Error bars represent the standard error of three technical replicates.](nihms-1593932-f0005){#F4}

![Inhibition of Dengue Infection through Targeted Inhibition of ITAM Signaling Pathway Elements\
(A) A small molecule that targets Syk tyrosine kinase (Syk TK), PRT, inhibited dengue infection in FcγRNa^**+**^FcγRNIa^**+**^ U937 monocytes.\
(B and C) A small-molecule inhibitor, INCA-6 (B), and a peptide inhibitor, 11R-VIVIT (VIVIT) (C), which act by blocking calcineurin-substrate interactions at the calcineurin PxIxIT site, inhibited dengue infections. A scrambled peptide containing the amino acids found in VIVIT (11R VEET) did not inhibit infection (open circles).\
(D) Inhibition of dengue viruses (DENV2, DENV3), but not H1N1 or H3N2 influenza viruses (IAVs), was observed using the VIVIT inhibitor (solid lines); scrambled VEET peptide in dashed lines.\
(E) Treatment of cells with VIVIT up to 6 h after infection by dengue immune complexes significantly inhibited infection.\
(F) Model for susceptibility to clinically significant dengue infections in infants. Infants of mothers who are dengue-immune and have ≥10% afucosylated anti-E IgGs are at elevated risk for symptomatic primary dengue infections due to modulation of FcγRIIIa-expressing cells during infection.\
(G) Model for the roles of FcγRIIa, FcγRIIIa, and afucosylated dengue immune complexes in ADE. While FcγRIIa supports a majority of viral attachment and entry, FcγRIIIa signaling increases cellular ITAM signaling. ITAM signaling, in turn, triggers calcium flux and modulates the calcineurin signaling network, which supports dengue virus replication.\
\*p \< 0.05, \*\*p \< 0.01, \*\*\*\*p \< 0.0001 (unpaired Student's t test). Data are representative of aminimum of three experiments. Error bars represent the standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol marking the data point.](nihms-1593932-f0006){#F5}

###### Highlights

-   Maternal anti-dengue afucosylation predicts symptomatic infections in infants

-   Afucosylated IgGs enhance dengue infections by promoting FcγRIMa signaling

-   Dengue virus replication required calcineurin signaling network interactions
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